Other Events ·
Evogene targets acute graft-versus-host disease with AI-driven small-molecule program
EVGNEvogene Ltd.
Evogene announced that its internal AI-driven drug discovery program will target acute graft-versus-host disease (aGVHD), a serious complication of hematopoietic stem cell transplantation affecting 30% to 40% of recipients. The company aims to develop a first-in-class small-molecule therapeutic for steroid-refractory patients, leveraging its ChemPass AI platform to explore over 110 billion molecules and generate novel candidates with optimized potency and safety profiles. Guided by experts from Dana-Farber Cancer Institute and University Medical Center Freiburg, Evogene has already identified lead series intended to advance toward IND-enabling studies within months. This initiative represents a strategic expansion of its proprietary therapeutic pipeline. Evogene is a computational chemistry company specializing in the generative design of small molecules for pharmaceutical and agricultural applications.